Completed PHASE2 INTERVENTIONAL 1-arm NCT00039442

Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer

A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix

Sponsor: Gynecologic Oncology Group

Conditions Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Recurrent Cervical Carcinoma

Interventions Capecitabine Laboratory Biomarker Analysis

Updated 7 times since 2017 Last updated: Aug 23, 2017 Started: Apr 29, 2002 Primary completion: Dec 7, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, this trial is completed. The trial is conducted by Gynecologic Oncology Group and has accumulated 7 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Feb 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Feb 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Sep 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Sep 2017 [monthly]

Completed PHASE2

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gynecologic Oncology Group
National Cancer Institute (NCI)

Data source: GOG Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Phoenix, United States